Regeneron Shares Rise 5% in 4 Days Since $1 Billion Upfront Sanofi Immunology Deal Expansion

Key numbers

Deal value	$1.0B
Share of market cap	1.3%
Share of annual revenue	7.0%

Key highlights

• Sanofi to pay Regeneron $1.0 billion in an upfront payment under the Sixth Amendment to their existing Antibody LCA
• Potential for up to $7.0 billion in development, regulatory, and commercial milestone payments for four new products
• Collaboration focuses on new long-acting antibodies targeting IL-13, IL-4, IL-4Ra, and a bispecific IL-4xIL-13
• Regeneron holds an option to include Sanofi's Phase 2/3 asset lunsekimig in the collaboration following clinical trials
• Global profits and development costs will be shared equally, with Regeneron leading U.S. regulatory activities

Expansion of Immunology Pipeline

Regeneron Pharmaceuticals and Sanofi Biotechnology SAS have signed the Sixth Amendment to their 2009 Antibody License and Collaboration Agreement. This expansion involves the joint development and commercialization of four new long-acting antibodies designed to treat inflammatory conditions. Under the terms, Sanofi will provide a $1.0 billion upfront payment and could pay up to $7.0 billion more based on clinical and commercial milestones. The assets target interleukin-13, interleukin-4, and the IL-4 receptor alpha, including a bispecific antibody. Regeneron will lead early development and U.S. regulatory filings, while Sanofi handles global commercialization and international regulatory submissions.

Strategic Significance and Options

This agreement strengthens the existing partnership that produced the blockbuster drug Dupixent, which also targets the IL-4 and IL-13 pathways. By securing an additional $1.0 billion in non-dilutive capital, Regeneron bolsters its research pipeline without impacting immediate cash reserves. The inclusion of an option for Sanofi's Phase 2/3 bispecific Nanobody, lunsekimig, provides a potential shortcut to late-stage commercialization in the respiratory and immunology sectors. Furthermore, the 50/50 profit-sharing structure ensures that Regeneron maintains a significant long-term stake in the commercial success of these next-generation biologics across global markets.

Operational Milestones

• Received U.S. FDA approval for Pasatru to treat fibrodysplasia ossificans progressiva in August 2026
• Awaiting FDA target action date for cemdisiran in generalized myasthenia gravis scheduled for November 2026
• Third quarter 2026 financial and operating results announcement scheduled for October 30, 2026
• Regeneron to lead regulatory party for marketing applications in the United States
• Sanofi to serve as lead regulatory party for marketing applications outside the United States

Financial and Market Context

Regeneron reported total revenues of $4.29 billion for the second quarter of 2026, contributing to an annual revenue base of $14.34 billion. The company currently holds a market capitalization of approximately $74.79 billion. With a price-to-earnings ratio of 17.96, the stock has recently seen a monthly price decrease of 14.74%, bringing its Relative Strength Index to 32.9. Trading volume remains consistent, with a weekly average of 805,620 shares. The company maintains a lead role in global biotechnology, utilizing its VelociSuite technologies to accelerate the discovery and production of fully human antibody treatments.

Up 3.7% since our story on 6 Oct: $726.47 when we broke it → $753.12 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$793.74
15 Sep	$774.11
16 Sep	$774.61
17 Sep	$789.45
18 Sep	$784.85
21 Sep	$798.17
22 Sep	$803.90
23 Sep	$801.82
24 Sep	$796.02
25 Sep	$788.04
28 Sep	$752.25
29 Sep	$750.51
30 Sep	$758.27
1 Oct	$734.81
2 Oct	$735.20
5 Oct	$726.47
6 Oct	$738.72
7 Oct	$742.12
8 Oct	$739.57
9 Oct	$746.54
12 Oct	$762.81
13 Oct	$753.12

REGENERON PHARMACEUTICALS, INC. · financial snapshot

Share price	$726.47
Market cap	$74.8B
Revenue (annual)	$14.3B
P/E (TTM)	18.0×
1-month price change	-14.74%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.